Background: The clinical diagnosis of amelanotic melanoma is still a challenge.

Case Report: A 72-year-old patient was first referred to us for the excision of a melanoma of the chin. In the first examination, we discovered another melanoma of the trunk. Both malignancies were excised and histopathology confirmed the clinical diagnosis of melanomas with Clark level II and III, respectively. Apart from these melanomas, physical examination revealed an 8 cm x 5 cm large erythematous plaque on the left upper arm. We first thought of a common eczema or a superficial mycosis; a cutaneous T cell lymphoma (CTCL) was considered as well. Surprisingly, the pathology report showed typical features of a malignant melanoma. The diagnosis was confirmed by 3 further punch biopsies (Clark level III, Breslow 0.6 mm). The lesion was excised with 1-cm safety margins.

Conclusions: Amelanotic melanoma may appear as an erythematous macula or plaque; clinical symptoms are erythema, edema, pruritus or a slow increase in size and hypopigmentation or discoloration. Only a biopsy can determine the etiology of a non-specific lesion.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000203334DOI Listing

Publication Analysis

Top Keywords

malignant melanoma
8
clinical diagnosis
8
amelanotic melanoma
8
clark level
8
level iii
8
melanoma
6
eczematous malignant
4
melanoma wolf
4
wolf sheep's
4
sheep's clothing
4

Similar Publications

Metastatic uveal melanoma (UM) patients often initially present with limited symptoms despite a poor prognosis, complicating communication with patients and caregivers. Early Together (NCT04728113) is a randomized Phase III trial that integrates early palliative care through systematic joint visits involving the palliative care team and the medical oncologist, compared with standard oncological care, in 162 metastatic UM patients beginning systemic treatment. This collaboration aims to enhance patient functioning, improve quality of life and facilitate coping mechanisms.

View Article and Find Full Text PDF

This study summarized the existing evidence on the outcomes and safety of anti-PD-1s, anti-PD-L1s and anti-CTLA-4s in pediatric patients with melanoma. MEDLINE and Embase were searched from database inception to 01-12-2023. Of 1537 records identified, 27 studies (k) of 64 patients were included.

View Article and Find Full Text PDF

Subungual melanoma accounts for 1.9% of cutaneous melanomas. Amelanotic cases, comprising 15-25%, poses a significant diagnostic challenge because it can be misdiagnosed as other traumatic, inflammatory, or neoplastic conditions.

View Article and Find Full Text PDF

This study determined the characteristics of patients with early-stage melanoma (IA-IIA) who later had stage IV recurrence. We retrospectively examined 880 melanoma patients and identified those who progressed to stage IV disease from an initial early-stage (n = 50). We observed a median latent period of 4 years between early-stage diagnosis and metastatic disease.

View Article and Find Full Text PDF

BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy.

Melanoma Manag

December 2024

Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Latina, Italy.

Aims: In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.

Patients And Methods: We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing immunotherapy or targeted therapy as first-line at a single center.

Results: A total of 88 patients diagnosed with melanoma were identified.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!